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Loss of apoptosis-inducing factor critically affects
MIA40 function
K Meyer1, S Buettner1, D Ghezzi2, M Zeviani3, D Bano*,1 and P Nicotera*,1
Mitochondrial apoptosis-inducing factor (AIF) influences the oxidative phosphorylation (OXPHOS) system and can be recruited as
a mediator of cell death. Pathogenic mutations in the AIFM1 gene cause severe human diseases. Clinical manifestations include
inherited peripheral neuropathies, prenatal cerebral abnormalities and progressive mitochondrial encephalomyopathies. In
humans, rodents and invertebrates, AIF deficiency results in loss of respiratory complexes and, therefore, impaired OXPHOS.
The molecular mechanisms underlying AIF-induced mitochondrial dysfunction remain elusive. Here we show that AIF physically
interacts with the oxidoreductase CHCHD4/MIA40. In patient-derived fibroblasts as well as in tissues and glia cells from Harlequin
(Hq) mutant mice, AIF deficiency correlates with decreased MIA40 protein levels, without affecting mRNA transcription.
Importantly, MIA40 overexpression counteracts loss of respiratory subunits in Hq cells. Together, our findings suggest that MIA40
reduction contributes to the effects of AIF deficiency on OXPHOS, as it may impact on the correct assembly and maintenance of
the respiratory subunits. This may be relevant for the development of new therapeutic approaches for AIF-related mitochondrial
disorders.
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Apoptosis-inducing factor (AIF) is an evolutionarily conserved
mitochondrial protein initially described as a death effector.1,2
The AIFM1 gene maps to the X-chromosome and gives rise to
a 67 kDa polypeptide that is imported into mitochondria in an
unfolded form. The processed 62 kDamature protein is mostly
tethered to the mitochondrial inner membrane through a
transmembrane domain, whereas a limited fraction is asso-
ciated with the outer membrane.3,4 As folded AIF incorporates
flavin adenine dinucleotide (FAD) and possess nicotinamide
adenine dinucleotide (NADH)-binding domains, it was initially
proposed that AIF could function as low-turnover oxidoreduc-
tase. However, a significant number of recent biochemical
data questioned this view and ruled out an antioxidant
function, despite its potential redox properties.5 Although its
enzymatic function remains unclear, AIF has emerged as a
critical pro-survival housekeeping component of the mito-
chondrial oxidative phosphorylation (OXPHOS). In various
cellular and animal models, AIF deficiency results in a general
loss of respiratory elements, which shows some tissue
specificity and is probably mediated by multiple factors,
including altered expression, assembly and maintenance of
the electron transport chain (ETC) subunits.6,7 Although
homozygous AIF-knockout mice are embryonic lethal,8
hypomorphic Harlequin (Hq) mutant mice are viable, although
they display severe phenotypes.9 Hq mice express ~ 20% of
normal AIF levels and exhibit reduced OXPHOS in various
tissues. As a consequence of mitochondrial abnormalities,
within 3–6 months of age Hq mice develop skeletal muscle
atrophy, astrogliosis as well as progressive retinal and
cerebellar neurodegeneration.9,10 Recently, several patho-
genic mutations in the AIFM1 gene were identified in
individuals exhibiting severe mitochondrial dysfunction, with
a clinical spectrum that includes maternally inherited periph-
eral neuropathies, prenatal ventriculomegaly, fatal and slowly
progressive encephalomyopathies and severe muscular
atrophy.11–15 It remains to be defined whether the hetero-
geneity, onset and severity of these clinical manifestations are
causally correlated with the extent of mitochondrial dysfunc-
tion. In general, mutations or a deletion of evolutionarily
conserved amino acids result in significantly decreased AIF
stability and, therefore, altered OXPHOS, although the under-
lying molecular mechanism remains unknown. Similarly to
other mitochondrial disorders, clinical interventions are very
limited.16–18
Here we searched for putative AIF interacting partners
that might mediate OXPHOS deficiency. Our results show
that mitochondrial intermembrane space import and assembly
40 (MIA40) co-immunoprecipitates with AIF. Importantly,
MIA40 requires AIF for the physiological protein availability
and function, resulting in an altered OXPHOS system in
cells lacking AIF. Our findings unveil a novel pathway that
may explain the loss of ETC subunits in individuals carrying
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AIF dysfunction, which may have significant implications
for novel therapeutic approaches.
Results
AIF deficiency significantly impairs OXPHOS in inverte-
brates, rodents and humans.6,9,11–13,19 As AIF does not
seem to interact with any ETC components,5,6,20,21 we hypo-
thesized that AIF influences OXPHOS maintenance through
an interaction with a protein relevant for protein folding or
ETC assembly. Thus, we used a yeast two-hybrid screening
to identify AIF interacting partners with a contributing
role in mitochondrial respiration. Using AIF as bait, we
identified coiled-coil-helix-coiled-coil-helix domain contain-
ing 4 (CHCHD4)/MIA40 as a putative candidate with high
confidence of interaction. MIA40 is a mitochondrial inter-
membrane space (IMS) protein that critically regulates the
import and folding of small IMS and inner membrane
proteins.22 Through a cascade of reversible redox reactions
and interaction with augmenter of liver regeneration (ALR)/
Erv1, MIA40 acts as a chaperone and contributes to the
assembly of inner membrane complexes, including ETC
components.23,24 Notably, altered MIA40-Erv1 function
causes an infantile mitochondrial disorder.25 To confirm the
identified candidate from the yeast two-hybrid screen, we
performed a co-immunoprecipitation assay in whole-cell
lysates and, using an anti-AIF antibody, we showed that
endogenous MIA40 interacted with AIF in vitro (Figure 1a).
Similarly, endogenous AIF was co-immunoprecipitated using
an anti-MIA40 antibody, confirming the physical binding
(Figure 1a). To further assess the AIF-MIA40 binding,
HEK293T cells were transiently transfected with green
fluorescent protein-tagged AIF, however the yield was very
low due to extensive cell death (data not shown). To
overcome this limitation, we generatedmutant AIF constructs
with decreased apoptogenic action 5,26 (Figure 1b). Speci-
fically, V5-tagged AIF lacking the N-terminal transmembrane
domain, the apoptotic cleavage sequence and the DNA-
binding sites were individually transfected to cells. The three
AIF mutant proteins localized correctly to the mitochondria
(Figure 1c). Using an anti-V5 antibody, we performed
immunoprecipitation assays in cellular lysates and found
that the transmembrane domain comprising residues 66–86
is critical for AIF binding to MIA40 (Figure 1d). Given the
described physical interaction between the two intermem-
brane proteins, we reasoned that AIF loss might affect whole
MIA40 abundance. In line with this hypothesis, a significant
decrease of MIA40 protein levels was found in brain tissue
and glia cells derived from Hq mice as well as in human
fibroblasts carrying the pathogenic AIFM1 (R201Δ)
deletion12 (Figures 1e and f). This effect appeared to be
posttranscriptional, given that quantitative RT-PCR of MIA40
messenger RNA (mRNA) levels showed no significant
change in the cerebellum of Hq mice compared with
littermate controls (Figure 1g). As MIA40 is involved in the
import and folding of both complex I subunits and complex IV
assembly factors,23,24 we hypothesized that overexpression
of MIA40 might rescue some of the ETC defects in AIF-
deficient cells. In line with our hypothesis, overexpression of
MIA40 in Hq mouse embryonic fibroblasts (MEFs) led to a
partial rescue of the complex I subunit NADH dehydrogenase
(ubiquinone) 1 beta subcomplex (NDUFB7) as well as the
complex IV subunit mitochondrially encoded cytochrome c
oxidase I (MTCO1) at the protein level (Figures 2a and b). On
the basis of these findings, AIF-mediated MIA40 stability is a
critical process required for the proper folding and main-
tenance of the respiratory complexes (Figure 2c).
Discussion
Mitochondria are critical regulators of cellular growth,
proliferation and death. They significantly contribute to energy
homeostasis by generating ATP through a series of redox
reactions generally known as OXPHOS. The OXPHOS
system comprises four respiratory chain complexes, two
mobile electron carriers and the ATP synthase, which converts
inorganic phosphate and ADP to ATP. A functional OXPHOS
system requires a large number of molecular chaperones that
control the proper assembly of over 90 individual proteins into
soluble and membrane-embedded multisubunit complexes.
Inherited mutations that affect mitochondrial bioenergetics
and function significantly contribute to the onset of several
human pathologies. In recent years, many pathogenic muta-
tions in theAIFM1 gene have been causally linked to disorders
exhibiting abnormal mitochondrial bioenergetics. Although the
role of AIF in cell death has been widely documented,5,27 little
is known about the mechanism through which AIF can affect
the respiratory capacity of the cell. As the identification of the
Hq mutation,9 it soon became evident that AIF has a
fundamental role in survival. The following studies in cellular
models confirmed that AIF deficiency primarily alters mito-
chondrial activity.6 As AIF has a NADH- and two FAD-binding
domains, it possesses an oxidorductase activity and
was, therefore, thought to act as an oxidant scavenger,
protecting the respiratory complexes from locally generated
reactive oxygen species. However, more recent biochemical
evidence questions this hypothesis,5,28 thereby leaving the
molecular mechanisms underlying AIF-mediated mitochon-
drial deficiency unexplained. Here we show for the first time
that AIF influences the stability of MIA40, which is a crucial
component of the IMS-import and assembly machinery of
cysteine-rich proteins.22 Such proteins are maintained in a
reduced form in the cytosol and undergo both import and
oxidative protein folding upon entry into the IMS in a MIA40-
dependent manner. The oxidative folding mechanism involves
a disulfide relay system in which electrons are shuttled from
the entering substrate to MIA40, to the sulfhydryl oxidase
Erv1/ALRand to a final electron acceptor, such as cytochrome c.
Among MIA40 substrates are several complex I (CI) subunits
and complex IV (CIV) assembly factors. As demonstrated in
tissues as well as in cells, AIF deficiency correlates with a
significant loss of MIA40 at the protein level. Importantly,
MIA40 overexpression is sufficient to rescue the loss of ETC
subunits in Hq cells. On the basis of our working hypothesis
(Figure 2c), we postulate that one of the AIF physiological
functions is to modulate the abundance aswell as the function of
the MIA40 protein. Theoretically, AIF may operate as a docking
protein, recruiting factor or redox intermediate for MIA40.
Reduced MIA40 functionality might result in an impaired import
or oxidative folding capacity, leading to a reduced abundance of
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its substrates, such as CI subunits and CIV assembly factors.
Therefore, the molecular binding between AIF and MIA40
would influence the correct assembly and maintenance of the
ETC. Our observations unveil a novel mechanism by which AIF
deficiency causesOXPHOS impairment. Thismaybe of relevance
in pathologies associated with mutations in the AIFM1 gene.
Materials and Methods
Antibodies. The following primary antibodies were used in this study: rabbit-
monoclonal AIF (Cell Signaling, Beverly, MA, USA); rabbit-polyclonal CHCHD4/
MIA40 and rabbit-polyclonal NDUFB7 (Proteintech, Chicago, IL, USA); mouse-
monoclonal V5, NDUFB8, NDUFA9, SDHB and total rodent OXPHOS antibody
cocktail (Abcam, Cambridge, UK); mouse-monoclonal tubulin (Sigma-Aldrich,
Munich, Germany); rabbit-polyclonal TOM20 (Santa Cruz, Santa Cruz
Figure 1 AIF interacts and regulates MIA40 protein. (a) Immunoblot analysis of AIF and MIA40 after immunoprecipitation (IP) with control IgG, AIF and MIA40 antibodies in
HEK293T cells. (b) Illustration of AIF mutants lacking its transmembrane domain (AIFΔ66-84), its apoptotic cleavage site (AIFΔ96-110) or its DNA-binding capacity (AIFK510A;K518A).
(c) Confocal imaging analysis of AIF mutants AIFΔ66-84-V5, AIFΔ96-110-V5 and AIFK510A;K518A-V5 using anti-V5 (green) and anti-Tom20 (red) antibodies. (d) Immunoblot analysis
of AIF and MIA40 after IP with control IgG, V5 and MIA40 antibodies in HEK293T cells overexpressing AIFΔ66-84-V5, AIFΔ96-110-V5 and AIFK510A;K518A-V5. (e and f) Immunoblot
and densitometry analysis of AIF, MIA40, NDUFB8 (CI), NDUFA9 (CI) and tubulin (as loading control) in cerebellum, cortex and glia cells derived from wild-type (wt) and Harlequin
(Hq) mice as well as human fibroblast cells derived from control (c) and patients (Pt) carrying the AIFM1 (R201Δ) deletion. (g) Quantitative RT-PCR analysis of CHCHD4/MIA40
in the cerebellum of 3 months old wild-type (wt) and Harlequin (Hq) mice. Values are plotted as means (+S.D.) and represent fold difference relative to control conditions. Asterisks
show statistical significance (unpaired Student's t-test, *Po0.05, **Po0.01, ***Po0.001)
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Biotechnology, Dallas, TX, USA). Goat anti-rabbit and anti-mouse HRP-conjugated
secondary antibodies were from Promega (Madison, WI, USA) and Pierce
(Darmstadt, Germany), respectively. Goat anti-mouse Alexa Fluor 488 and anti-
rabbit Alexa Fluor 568 were from Life Technologies (Darmstadt, Germany).
Cell culture and transfection. HEK293T cells, human patient fibroblast,
MEFs and glia cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum (Gibco, Darmstadt, Germany) and 1%
penicillin–streptomycin (Gibco). Cells were incubated at 37 °C in a humidified
incubator with 5% CO2. HEK293T cells were transfected using a calcium
phosphate-based method. Human fibroblasts were transfected using Lipofectamin
3000 (Life Technologies). Lipofectamine was incubated in Opti-MEM for 10 min at
room temperature, after which plasmid-DNA was added. The DNA-Lipofectamine
solution was then incubated for 40 min at room temperature on a shaking wheel and
finally added to cells, which were incubated in Opti-MEM (Life Technologies) at least
1 h before the transfection. Fresh media was added 2 h after transfection.
Confocal analysis. Imaging analysis was performed using a Zeiss
LSM 700 microscope (Zeiss, Oberkochen, Germany) with a 63 × immersion
lens. Images were analysed and processed using Zen (Zen Software Ltd,
Rochdale, UK) and ImageJ software. Before analysis, cells were cultured on
cover slips, fixed for 5 min with 4% paraformaldehyde at 37 °C in a humidified
incubator. Immunostaining was performed using primary anti-V5, anti-TOM20
antibodies and secondary Alexa Fluor 488 and Alexa Fluor 568 antibodies.
Immunoprecipitation. For each immunoprecipitation 250 μg of protein was
used and incubated for 30 min at 4 °C with protein A-agarose (Sigma-Aldrich) to
reduce unspecific binding. The supernatant was incubated with the primary
antibody overnight at 4 °C. The next day the lysate was incubated with fresh
protein A-agarose for 2 h at room temperature and afterwards the pellet was
washed three times with RIPA buffer. Finally, the protein A-agarose pellet was
resuspended in Laemmli-buffer, heated to 95 °C for 5 min and subjected to
western blot analysis.
Figure 2 MIA40 overexpression ameliorates ETC deficiency in Hq MEFs. (a and b) Immunoblot and densitometry analysis of AIF, MIA40, NDUFB7 (CI), mitochondrially
encoded cytochrome c oxidase I (CIV), SDHB (CII), CHCHD4/MIA40, myc-tagged CHCHD4/MIA40 and tubulin in wt and Hq MEFs transiently transfected with mitochondria-
targeted green fluorescent protein (− ) or MIA40-myc (+) plasmids. Endogenous CHCHD4/MIA40 (o) and myc-tagged CHCHD4/MIA40 (oo) are indicated. Values are plotted
as means (+S.D.) and represent fold difference relative to control conditions. Asterisks show statistical significance (One-way ANOVA with Tukey´s multiple comparisons test
**Po0.01, *Po0.05, NS, non-significant). (c) Schematic representation of a simplified proposed working model. MIA40 substrates, such as CI subunits and CIV assembly
factors are imported into mitochondria via the TOM complex. MIA40 binding to AIF results in efficient oxidative protein folding and ETC assembly
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Mitochondrial enrichment. Mitochondria were enriched before immuno
precipitation. Briefly, cells were collected and washed once with PBS. Then, the cell
pellet was resuspended in IB buffer (10 mM Tris/MOPS, 1 mM EGTA/Tris, 2 mM
sucrose, pH 7.4) and homogenized using a glass/teflon homogenizer. The
homogenate was centrifuged 600 × g at 4 °C for 10 min. The supernatant was
centrifuged and washed twice with IB buffer at 7000 × g at 4 °C for 10 min. The
mitochondrial pellet was finally resuspended in RIPA buffer (Sigma-Aldrich),
supplemented with protease and phosphatase inhibitor cocktail (Roche, Mannheim,
Germany), sonicated and the protein concentration was determined by Bradford
assay (Biorad, Hercules, CA, USA).
Plasmids. The plasmid encoding CHCHD4-myc-DDK were obtained from
OriGene (Rockville, MD, USA). The AIFΔ96-110-V5, AIFK510A;K518A-V5, AIFΔ66-84-V5
constructs in pLenti6.2-V5 were obtained from Life Technologies.
Quantitative real-time PCR. RNA extraction, purification and reverse
transcription were performed by using the QIAshredder, RNeasy RNA extraction
kit (Qiagen, Hilden, Germany) and qScript cDNA SuperMix (Quanta Biosciences,
Gaithersburg, MD, USA ). Quantitative RT-PCR was carried out in a Step One Plus
Real time PCR System (Applied Biosystems, Darmstadt, Germany) and analyzed
using the comparative ΔΔCt method. mRNA levels of beta-actin were used for
normalization. The average of at least three technical repeats was used for each
biological data point. The sequences of the oligonucleotides that were used are the
following: mouse beta-actin: 5′-ggtggttcctccggaaagaa-3′; 5′-tgcgacattgatatccgtaagg-3′
mouse CHCHD4/MIA40: 5′-cgggaacaaccatgtcctac-3′; 5′-tcatggtcttctttggtcacaa-3′.
SDS-PAGE and western blotting. Wild-type and Harlequin tissues as well
as HEK293T, human patient fibroblast, MEFs and glia cells were lysed in RIPA buffer
supplemented with protease and phosphatase inhibitors (Roche). Protein concentra-
tion was determined by Bradford assay and 20 μg of protein was separated on a 12%
SDS-acrylamide gel. Subsequently, the proteins were transferred onto a nitrocellulose
membrane (Biorad), incubated with the desired primary antibody, followed by
incubation with the appropriate secondary antibody. Chemiluminescent signals of
enhanced detection substrates (Thermo Scientific, Darmstadt, Germany) were
collected using a CCD camera-equipped ChemiDoc MP system (Biorad).
Yeast two-hybrid analysis. Yeast two-hybrid screening was performed by
Hybrigenics Services, S.A.S (Paris, France). The coding sequence for Mus
musculus Aifm1 (aa 102–612) (GenBank accession number GI:594150366) was
PCR amplified and cloned into pB27 as a C-terminal fusion to LexA (N-LexA-Aifm1–C
fusion). The entire insert was sequenced and used as a bait to screen a random-
primed Mouse Adult Brain cDNA library constructed into pP6. Approximately 79.6
million clones were screened using a mating approach with YHGX13 (Y187 ade2-
101::loxP-kanMX-loxP, matα) and L40ΔGal4 (mata) yeast strains. On a medium
lacking tryptophan, leucine and histidine, 302 His+ colonies were selected. The prey
fragments of the positive clones were amplified by PCR and sequenced at their 5′ and
3′ junctions. The resulting sequences were used to identify the corresponding interacting
proteins in the GenBank database (NCBI) using a fully automated procedure.
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